Should NSCLC Patients Receive Immunotherapy 'Indefinitely'?
Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.
Source: medscape.com
Conore Steuer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Conore Steuer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Conore Steuer Today - Breaking & Trending Today
Daiichi Sankyo: Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort
Source: finanznachrichten.de